Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis

Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist and is under development for the treatment of type 2 diabetes (T2D) and obesity. Its association with cardiovascular outcomes requires evaluation. This pre-specified cardiovascular meta-analysis included all seven randomized contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Sattar, Naveed, McGuire, Darren K., Pavo, Imre, Weerakkody, Govinda J., Nishiyama, Hiroshi, Wiese, Russell J., Zoungas, Sophia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938269/
https://www.ncbi.nlm.nih.gov/pubmed/35210595
http://dx.doi.org/10.1038/s41591-022-01707-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938269/
https://www.ncbi.nlm.nih.gov/pubmed/35210595
http://dx.doi.org/10.1038/s41591-022-01707-4

Ejemplares similares